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A B S T R A C T
Background
Asthma is a chronic inflammatory disease that affects the airways and is common in both adults and children. It is characterised by
symptoms including wheeze, shortness of breath, chest tightness, and cough. People with asthma may be helped to manage their
condition through shared decision-making (SDM). SDM involves at least two participants (the medical practitioner and the patient)
and mutual sharing of information, including the patient’s values and preferences, to build consensus about favoured treatment that
culminates in an agreed action. Effective self-management is particularly important for people with asthma, and SDM may improve
clinical outcomes and quality of life by educating patients and empowering them to be actively involved in their own health.
Objectives
To assess benefits and potential harms of shared decision-making for adults and children with asthma.
Search methods
We searched the Cochrane Airways Trials Register, which contains studies identified in several sources including CENTRAL, MED-
LINE, and Embase. We also searched clinical trials registries and checked the reference lists of included studies. We conducted the
most recent searches on 29 November 2016.
Selection criteria
We included studies of individual or cluster parallel randomised controlled design conducted to compare an SDM intervention for
adults and children with asthma versus a control intervention. We included studies available as full-text reports, those published as
abstracts only, and unpublished data, and we placed no restrictions on place, date, or language of publication. We included interventions
targeting healthcare professionals or patients, their families or care-givers, or both. We included studies that compared the intervention
versus usual care or a minimal control intervention, and those that compared an SDM intervention against another active intervention.
We excluded studies of interventions that involved multiple components other than the SDM intervention unless the control group
also received these interventions.
Data collection and analysis
Two review authors independently screened searches, extracted data from included studies, and assessed risk of bias. Primary outcomes
were asthma-related quality of life, patient/parent satisfaction, and medication adherence. Secondary outcomes included exacerbations
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of asthma, asthma control, acceptability/feasibility from the perspective of healthcare professionals, and all adverse events. We graded
and presented evidence in a ’Summary of findings’ table.
We were unable to pool any of the extracted outcome data owing to clinical and methodological heterogeneity but presented findings
in forest plots when possible. We narratively described skewed data.
Main results
We included four studies that compared SDM versus control and included a total of 1342 participants. Three studies recruited children
with asthma and their care-givers, and one recruited adults with asthma. Three studies took place in the United States, and one in the
Netherlands. Trial duration was between 6 and 24 months. One trial delivered the SDM intervention to the medical practitioner, and
three trials delivered the SDM intervention directly to the participant. Two paediatric studies involved use of an online portal, followed
by face-to-face consultations. One study delivered an SDM intervention or a clinical decision-making intervention through a mixture
of face-to-face consultations and telephone calls. The final study randomised paediatric general practice physicians to receive a seminar
programme promoting application of SDM principles. All trials were open-label, although one study, which delivered the intervention
to physicians, stated that participants were unaware of their physicians’ involvement in the trial. We had concerns about selection and
attrition bias and selective reporting, and we noted that one study substantially under-recruited participants. The four included studies
used different approaches to measure fidelity/intervention adherence and to report study findings.
One study involving adults with poorly controlled asthma reported improved quality of life (QOL) for the SDM group compared
with the control group, using the Asthma Quality of Life Questionnaire (AQLQ) for assessment (mean difference (MD) 1.90, 95%
confidence interval (CI) 1.24 to 2.91), but two other trials did not identify a benefit. Patient/parent satisfaction with the performance
of paediatricians was greater in the SDM group in one trial involving children. Medication adherence was better in the SDM group
in two studies - one involving adults and one involving children (all medication adherence: MD 0.21, 95% CI 0.11 to 0.31; mean
number of controlled medication prescriptions over 26 weeks: 1.1 in the SDM group (n = 26) and 0.7 in the control group (n = 27)).
In one study, asthma-related visit rates were lower in the SDM group than in the usual care group (1.0/y vs 1.4/y; P = 0.016), but
two other studies did not report a difference in exacerbations nor in prescriptions for short courses of oral steroids. Finally, one study
described better odds of reporting no asthma problems in the SDM group than in the usual care group (odds ratio (OR) 1.90, 95%
CI 1.26 to 2.87), although two other studies reporting asthma control did not identify a benefit with SDM. We found no information
about acceptability of the intervention to the healthcare professional and no information on adverse events. Overall, our confidence in
study results ranged from very low to moderate, and we downgraded outcomes owing to risk of bias, imprecision, and indirectness.
Authors’ conclusions
Substantial differences between the four included randomised controlled trials (RCTs) indicate that we cannot provide meaningful
overall conclusions. Individual studies demonstrated some benefits of SDM over control, in terms of quality of life; patient and parent
satisfaction; adherence to prescribed medication; reduction in asthma-related healthcare visits; and improved asthma control. Our
confidence in the findings of these individual studies ranges from moderate to very low, and it is important to note that studies did not
measure or report adverse events.
Future trials should be adequately powered and of sufficient duration to detect differences in patient-important outcomes such as
exacerbations and hospitalisations. Use of core asthma outcomes and validated scales when possible would facilitate future meta-
analysis. Studies conducted in lower-income settings and including an economic evaluation would be of interest. Investigators should
systematically record adverse events, even if none are anticipated. Studies identified to date have not included adolescents; future trials
should consider their inclusion. Measuring and reporting of intervention fidelity is also recommended.
P L A I N L A N G U A G E S U M M A R Y
Can shared decision-making between the patient and the healthcare professional help people with asthma?
Background to the question
Asthma is a long-term disease that is common in adults and children. People with asthma often wheeze, cough, and have difficulty
breathing. Shared decision-making means fully involving individuals with asthma in decisions about their care. It usually involves the
patient and his or her doctor or nurse, and key features include sharing information to help individuals with asthma make the best
decisions for themselves. By including individuals with asthma in the decision-making process, it is hoped that their asthma will be
better controlled and will cause them fewer problems.
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Review question
Wewanted to review the evidence on shared decision-making for people with asthma compared with standard asthma care, or a different
way of making healthcare decisions. We wanted to know if shared decision-making has an effect on quality of life, asthma attacks,
patient satisfaction with care, asthma control, sticking to medication plans, and unwanted effects.
Study characteristics
We reviewed the evidence up toNovember 2016. We found four studies, including 1342 people, that attempted to answer this question.
All participants had asthma; participants in three studies were children and those in one study were adults. Three studies took place in
the United States and one in the Netherlands; studies lasted from six months to two years. Different studies used different methods of
shared decision-making, including face-to-face discussions, telephone calls, and online messages.
Key results
Because these studies were conducted in different ways, we were unable to combine their findings. We found evidence from individual
studies indicating that shared decision-making may improve quality of life and asthma control and may reduce healthcare visits for
asthma. Shared decision-making may also help people to take their asthma inhaler(s) more regularly owing to better understanding of
why they need to do that. Going through this process may make people feel more satisfied with their care, as they may feel empowered
about making choices. However, all of these findings were reported by different studies, and some studies showed benefit of shared
decision-making, while others did not. It is important to mention that none of these studies looked into whether shared decision-
making causes unwanted side effects. All four studies measured how well the shared decision-making intervention had been delivered
or received but did this in different ways.
Quality of the evidence
We were not very confident in the quality of the evidence presented in this review. We were concerned about the small number of
studies and about differences in the way included studies were designed. Also, participants knew which group they were in (i.e. shared
decision-making or standard care), and this may have affected how they answered questions about their asthma during the trial.
Take-home message
Some evidence suggests that shared decision-making might help people with asthma, but we are not sure whether it is helpful. In the
future, larger studies that include adolescents while looking out for side effects, harms, and benefits should prove useful in answering
this question.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Shared decision-making compared with usual care for people with asthma
Patient or population: adults and children with asthma
Setting: primary care/ outpat ient clinics
Intervention: shared decision-making
Comparison: usual care
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with usual care Risk with shared de-
cision-making
Asthma-related
quality of lif e
(follow-up: 6 to 24
months)
AQLQ responders 556 per 1000 704 per 1000
(608 to 784)
OR 1.90
(1.24 to 2.91)
371
(1 RCT)
⊕⊕⊕©
MODERATEa
Part icipants achiev-
ing > 0.5-point im-
provement (MCID
for this scale)
ITG-ASF dayt ime
symptom scale
Mean ITG-ASF day-
t ime symptom score
was 12
MD 4 higher
(3.54 lower to 11.54
higher)
- 53
(1 RCT)
⊕©©©
VERY LOWa,b,c
Higher score = Bet-
ter quality of lif e
The same study
also reported mean
night-t ime symptom
scale and funct ional
lim itat ion scale (see
Analysis 1.2).
M ini-AQLQ Mini-AQLQ score
was 5.5
MD 0.4 higher
(0.18 higher to 0.62
higher)
- 371
(1 RCT)
⊕⊕©©
LOWa,c,d
Higher score = Bet-
ter quality of lif e.
MCID 0.5
Parent/ pat ient sat isfact ion Presentat ion on forest plot not possible;
summarised narrat ively in text and Table 2
- - -
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Medicat ion adher-
ence
(follow-up: 12 to 24
months)
ICS only The ICS adherence
was 0.59
MD 0.22 higher
(0.11 higher to 0.33
higher)
- 371
(1 RCT)
⊕⊕⊕©
MODERATEe
Adher-
ence calculated us-
ing cont inuous med-
icat ion acquisit ion
(CMA) f rom phar-
macy data. Maxi-
mum score 1
The same study re-
ported all-medica-
t ion adherence (see
Analysis 1.4).
Exacerbat ions of
asthma
(follow-up: 6
months)
Requiring ED visit 222 per 1,000 77 per 1,000
(14 to 314)
OR 0.29
(0.05 to 1.60)
53
(1 RCT)
⊕⊕©©
LOWf
The same study re-
ported ex-
acerbat ions requir-
ing hospital admis-
sion, ‘‘specialist vis-
its’’, and GP visits
(see Analysis 1.5).
Asthma control
(follow-up: 12 to 24
months)
Asthma well con-
trolled; ATAQ = 0
No control group
risk presented
Not est imable OR 1.90
(1.26 to 2.87)
371
(1 RCT)
⊕⊕⊕©
MODERATEa
Lower score = Better
asthma control
A dif fer-
ent small study re-
ported asthma con-
trol on ACT and ACQ
(see Analysis 1.6).
Adverse events (all) Included trials did not measure or report
any adverse events
- - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ACQ: Asthma Control Quest ionnaire; ACT: Asthma Control Test; AQLQ: asthma quality of lif e quest ionnaire; ATAQ: Asthma Therapy Assessment Quest ionnaire CI: conf idence
interval; ED: emergency department; GP: general pract it ioner; ICS: inhaled cort icosteroid; ITG-ASF: Integrated Therapeut ics Group - Child Asthma Short Form; MCID: mean
clinically important dif f erence; MD: mean dif ference; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io.5
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aRisk of performance and detected bias. Downgraded once.
bOne study. Conf idence intervals include possible harm and benef it of intervent ion. Downgraded once.
cOnly quality of lif e subscales reported. Downgraded once for indirectness.
dAlthough the mean dif ference for this scale lies below the MCID, the responder analysis suggests that signif icant ly more
people achieved the MCID change with the intervent ion. No downgrade.
eAdherence calculated using cont inuous medicat ion acquisit ion f rom pharmacy data. This is a proxy measure and may
overest imate true adherence. Downgraded once.
fOne study. Conf idence intervals very wide and include possible harm and benef it of intervent ion. Downgraded twice.
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B A C K G R O U N D
Description of the condition
Asthma is a chronic disease that affects the airways. It is usu-
ally characterised by chronic inflammation of the airways, which
causes wheeze, shortness of breath, chest tightness, cough, and
variable airflow limitation (GINA 2016). Symptoms vary signif-
icantly in nature, frequency, and severity, both within and be-
tween individuals with a diagnosis of asthma. Day-to-day symp-
toms vary according to the presence of external stimuli (e.g. exer-
cise, allergens), and people with asthma can experience flare-ups
or ’exacerbations’, which are associated with significant morbidity
and mortality worldwide (GINA 2016; Global Asthma Network
2014; NRAD 2014). Long-term goals of asthma management in-
cludemaintaining control of symptoms andminimising risk of ex-
acerbations, airflow limitation, and treatment side effects (GINA
2016). Educating adults and children to self-manage their asthma
is widely recognised as integral to achieving these goals (Gibson
2002; Guevara 2003).
Description of the intervention
Shared decision-making (SDM) should involve at least two partic-
ipants (the medical practitioner and the patient) and is defined as
mutual sharing of information to build consensus about preferred
treatment that culminates in an agreed action (Charles 1997). De-
cisions about management of long-term conditions are based on a
multitude of factors, including relative efficacy and safety of treat-
ments, costs, and palatability. Shared decision-making provides a
way of balancing these factors by considering the values and pref-
erences of the patient and the opinions of healthcare providers.
Légaré describes the three essential elements of SDM as follows
(Légaré 2013).
1. Recognizing and acknowledging that a decision is required.
2. Knowing and understanding the best available evidence.
3. Incorporating the patient’s values and preferences into all
decisions.
For asthma, management guidelines increasingly acknowledge the
role of “the patient and healthcare provider partnership” for a
shared-care approach (GINA2016). Interventions provided to en-
courage patient-centred care in clinical consultations across a range
of conditions generally put the onus on the healthcare provider;
some seek to offer a pathway for patients or parents to better
engage in their asthma care; and others suggest a combination
of these approaches (Dwamena 2012; Fiks 2015; Wilson 2010).
Thus different approaches may have different aims and outcomes.
Interventions aimed at changing healthcare provider behaviour
might include open communications, efforts to identify and ad-
dress patient and family concerns about asthma and its treatment,
discussion of treatment preferences and barriers to implementa-
tion, shared development of treatment goals, and encouragement
of active self-assessment and self-management (NHLBI/NAEPP
2007).
How the intervention might work
The potential benefit of SDM is dependent on the willingness and
ability of both sides to interact, and this ability might depend on
factors such as “ethnicity, literacy, understanding of health con-
cepts (health literacy), numeracy, beliefs about asthma and medi-
cations, desire for autonomy, and the health care system” (GINA
2016). As such, SDM will not necessarily be equally acceptable
to all patients or care-givers and may not be applied in the same
way across healthcare contexts. Benefits of SDM may be seen for
individuals and more widely for health services and society as en-
hanced uptake of evidence-based options and reduction in overuse
of options that confer minimal benefit, thus reducing practice and
geographic variations in care and avoiding unnecessary expendi-
tures (Coulter 2011; Légaré 2014).
Preferences for an active, collaborative, or passive role in decision-
making vary among populations, but patient roles are often pas-
sive, and many patients report that they wish to be more involved
(Caress 2005; Sleath 2011). Patient preferences for involvement
in decision-making are related to education level, perceptions of
the healthcare provider, financial barriers to receiving appropri-
ate care, and psychosocial factors, but preferences have not been
strongly associated with demography or asthma severity (Adams
2001; Caress 2005). Nonetheless, evidence regarding how best to
achieve SDM in practice is sparse, especially in paediatric asthma
with regards to the child-parent relationship and adapted empha-
sis on SDM as the child matures (Rivera-Spoljaric 2014).
Researchers have highlighted organisational factors that may serve
as a barrier to feelings of satisfaction among patients or families
regarding the role they play in their asthma care, especially qual-
ity and duration of consultations, which vary substantially across
healthcare contexts (Caress 2005). A narrative synthesis of the
fast-growing trend toward patient involvement in medicine has
identified that the preparedness of service systems can enable suc-
cessful SDM, alongside empowerment, patient education, com-
munication for involvement, and staff training (Snyder 2016). It
is possible that engaging in SDM may cause unintended harms,
for example, by allowing a patient to choose an option without
proper discussion of harms and benefits, so it is important that
staff are appropriately trained, and that decision aids are used cor-
rectly (Coulter 2011).
Why it is important to do this review
Shared decision-making (SDM) may improve clinical outcomes
and quality of life by educating and empowering patients to be
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actively involved in their own health (Butz 2007; Wilson 2010).
These interventions may be particularly beneficial in people with
asthma, as self-management behaviours are important for, and
make SDM particularly relevant to, the population with asthma
(Gibson 2002; Guevara 2003). The US Institute of Medicine has
prioritised SDM, and Asthma UK has identified methods to “em-
power and enable people to take control of their own asthma” as a
research priority (Asthma UK 2011; Institute of Medicine 2009).
A recent Cochrane review found 43 studies that tested effects of
interventions to encourage patient-centred care in clinical consul-
tations, and found mixed results in terms of patient satisfaction,
health behaviour, and health status (Dwamena 2012). Review au-
thors suggested that complex interventionswith condition-specific
materials aimed at both providers and patients might be promis-
ing, but acknowledge that evidence was limited at the time. Simi-
larly, Légaré focused on interventions aimed at improving uptake
of SDMby healthcare professionals acrossmedical disciplines with
a primary focus on how well this is adopted in practice (Légaré
2014). Review of available evidence for SDM in asthma will allow
us to conduct wider searches of the asthma literature to find ad-
ditional studies and to focus on important condition-specific out-
comes. Attention to clinical outcomes is particularly important,
given the possible tension between SDM and adherence to clinical
guidelines. Growth of SDM research means it is likely that new
evidence will have been published since the time existing reviews
were prepared.
O B J E C T I V E S
To assess benefits and potential harms of shared decision-making
for adults and children with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that used indi-
vidual or cluster randomisation. We planned to exclude cross-over
trials; however, we will include the first phase of cross-over trials
in future versions of the review. We did not identify any relevant
cross-over studies. We excluded non-randomised studies because
they would restrict our ability to imply causation of intervention
effects and are more likely to be subject to selection biases and
confounders. However, we summarised narratively any non-ran-
domised evidence identified by our searches and contrasted this
summary with results presented in our discussion. We planned
to include studies reported as full-text articles, those published as
abstracts only, and unpublished data.
Types of participants
We included studies of adults and children with a diagnosis of
asthma, confirmed by a medical practitioner or by spirometry ac-
cording to guidelines (e.g. GINA 2016). We excluded studies that
included participants with other long-term conditions, in par-
ticular, chronic obstructive pulmonary disease (COPD), unless
researchers presented separate results for those with asthma. We
also excluded studies looking at shared decision-making (SDM)
in asthma specifically for people with cognitive impairments, as
these interventions are likely to have a different focus. If a study
included a subset of eligible participants (e.g. a mixed population
that includes participants with other health conditions), we in-
cluded it only if we could analyse separately disaggregated data for
eligible participants.
Types of interventions
We included studies that assessed SDM interventions for people
with asthma. We included interventions aimed at healthcare pro-
fessionals (specialists, general practitioners, nurses, pharmacists,
etc.), patients and their families or care-givers, or both. We in-
cluded studies that compared the intervention against usual care
or a minimal control intervention and those compared an SDM
intervention versus another active intervention, such as clinical de-
cision-making. We excluded studies of interventions that involved
multiple components other than the SDM intervention unless the
control group also received these components.
Types of outcome measures
Primary outcomes
1. Asthma-related quality of life (on a validated scale e.g.
Asthma Quality of Life Questionnaire (AQLQ))
2. Patient/parent satisfaction
3. Medication adherence
Secondary outcomes
1. Exacerbations of asthma (leading to a course of oral
corticosteroid (OCS) treatment or an unscheduled visit to a
healthcare professional)
2. Asthma control (e.g. Asthma Control Questionnaire
(ACQ))
3. Acceptability/feasibility from the perspective of healthcare
professionals
4. Adverse events (all)
Reporting one or more of the outcomes listed here was not a
criterion for inclusion of studies in this review.
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Trial authors and editorial teams chose primary outcomes by con-
sensus as those most likely to be relevant to the intervention under
investigation and most important to patients and their families/
care-givers.
We prioritised extraction of any validated measures of patient/
parent satisfaction, medication adherence, asthma control, and
acceptability/feasibility but did not predefine acceptedmeasures in
advance, so as not to restrict analyses unnecessarily. If study authors
used non-validated measures, or used a mixture of validated and
non-validated measures across studies, we planned to assess which
were sufficiently similar for pooling to make sense.
We planned to extract and analyse data from both parent and child
perspectives as provided by paediatric studies.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP.
5. Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL EBSCO).
6. Monthly searches of the Allied and Complementary
Medicine database (AMED EBSCO).
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register were identified through
search strategies based on the scope of Cochrane Airways. We have
presented inAppendix 1 details of these strategies, as well as a list of
handsearched conference proceedings.See Appendix 2 for search
terms used to identify studies for this review. We based our search
terms for ’shared decision-making’ on those used in a Cochrane
Review by Légaré (Légaré 2014).
We also conducted a search of ClinicalTrials.gov (http://
ClinicalTrials.gov) and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP; http://
who.int/ictrp/en/). We searched all databases from their inception
to the present, and we imposed no restriction on language of pub-
lication. We conducted the most recent searches on 29 November
2016.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.
On 15 November 2016, we searched for errata or retractions
from included studies published in full text on PubMed (http://
ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (KK and RN) independently screened titles
and abstracts for inclusion of all potential studies identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved full-text
study reports/publications for all studies in the ’retrieve’ category.
Two review authors (KK and PM) independently screened full-
text articles and identified studies for inclusion, and identified and
recorded reasons for exclusion of ineligible studies. We resolved
disagreements through discussion; if required, we consulted a third
person. We identified and excluded duplicates and collated multi-
ple reports of the same study, so that each study, rather than each
report, was the unit of interest in the review.We recorded the selec-
tion process in sufficient detail to complete a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram (Figure 1) and Characteristics of excluded studies tables
(Moher 2009).
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Figure 1. Study flow diagram.
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Data extraction and management
We used a data collection form piloted on one included study
to record study characteristics and outcome data. One review au-
thor (KK) extracted the following study characteristics from the
included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, and dates of the study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (KK and RN) independently extracted out-
come data from included studies. We noted in the Characteristics
of included studies table if a study reported outcome data that
were not useable in an analysis. We resolved disagreements by
reaching consensus or by involving a third person. One review
author (KK) transferred data into the Review Manager (RevMan)
file (RevMan 2014). We double-checked that data were entered
correctly by comparing data presented in the systematic review
versus data provided in the study reports.
Assessment of risk of bias in included studies
Two review authors (KK and RN) independently assessed risk
of bias for each included study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).We resolved disagreements by discussion or by consultation
with a third person. We assessed the risk of bias of each included
study according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
’Risk of bias’ judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for a
patient-reported pain scale).When information on risk of bias was
related to unpublished data or correspondence with a trial author,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for each study that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean differences. Had we been able to combine data presented
on different scales, we planned to use standardised mean differ-
ences. We entered data presented as a scale with a consistent di-
rection of effect.
We planned to undertake meta-analyses only when this was mean-
ingful (i.e. if treatments, participants, and the underlying clinical
question were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
When a single study reported multiple trial arms, we planned to
include only the relevant arms. If we had combined two compar-
isons (e.g. two types of SDM vs usual care) in the same meta-
analysis, we planned to halve the control group to avoid double
counting.
If both change from baseline and endpoint scores were available
for continuous data, we planned to use change from baseline un-
less most studies reported endpoint scores. If a study reported out-
comes at multiple time points, we used the end-of-study measure-
ment.
If both an analysis that included only participants who completed
the trial and an analysis that imputed data for participants who
were randomly assigned but did not provide endpoint data (e.g.
last observation carried forward) were available, we planned to use
the latter.
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis (i.e. number of people admitted with
one or more exacerbation, rather than number of exacerbations
per person). We planned to meta-analyse data from cluster RCTs
only if available data had been adjusted (or could be adjusted) to
account for clustering.
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Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
data when possible (e.g. when we identify a study as an abstract
only). However, we identified full-text reports of all included stud-
ies.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the studies in each analysis. If we had identified substantial hetero-
geneity, we planned to report this and to explore possible causes
by conducting prespecified subgroup analyses.
Assessment of reporting biases
We were not able to pool more than 10 studies, so we could not
create and examine a funnel plot to explore possible small-study
and publication biases.
Data synthesis
We planned to use a random-effects model and to perform a sen-
sitivity analysis using a fixed-effect model.
’Summary of findings’ table
We created a ’Summary of findings’ table using the outcomes listed
in this review. We used the five Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) considerations
(study limitations, consistency of effect, imprecision, indirectness,
and publication bias) to assess the quality of a body of evidence
as it relates to studies that contributed data to meta-analyses for
prespecified outcomes. We used methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), and we
used the GRADEpro Guideline Development Tool (GRADEpro
GDT). We used footnotes to justify all decisions to downgrade or
upgrade the quality of the evidence, and we made comments to
aid the reader’s understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analysesa for primary out-
comes.
1. Age of the asthma population (children < 12 years of age,
12 to 18 years of age, adults > 18 years of age).
2. Focus of the intervention (i.e. population randomised to
the intervention: healthcare providers vs patients/parents).
3. Duration/extensiveness of intervention (e.g. one-off or
simple intervention vs ongoing SDM sessions).
aChildren, adolescents, and adults may have quite different needs
and preferences with respect to SDM, so interventions may have
different focuses and effects across age groups. We expected study
effects to vary regarding focus and extent of the intervention, and
we tried to assess this in the other two subgroup analyses.However,
a subgroup analysis can look at only one of these effect modifiers
at a time and does not imply causation; therefore, we planned
to interpret the results cautiously. We presented these and other
possible effect modifiers in Table 1.
We planned to use the formal test for subgroup interactions pro-
vided in RevMan (RevMan 2014).
Sensitivity analysis
We planned to perform the following sensitivity analyses by re-
moving the following from the primary analyses.
1. Unpublished data.
2. Studies at high risk in any selection bias domain.
R E S U L T S
Description of studies
Results of the search
We identified 152 records in main database searches (including
a search of clinicaltrials.gov), 21 from the WHO trials portal,
four from reference lists of included studies, and one through
author correspondence. We found that four were duplicates, and
we screened the remaining 174 records. We excluded 137 records
that did not meet review inclusion criteria by looking at titles
and abstracts, and we obtained full texts for the 37 remaining
records. After reviewing full texts, we deemed that 21 records were
ineligible for inclusion in the review: 16 because they did not
meet the inclusion criteria and five because they were ongoing
studies (related to four studies: Federman 2015; Hoskins 2013;
NCT02516449; Tapp 2011).We collated the 16 excluded records
into 11 unique studies, which we have described under Excluded
studies. We collated the other 17 records into four unique studies
and included them in the review (Figure 1).
We conducted a further search on 27 June 2017 before preparation
of this publication.One study investigating the use of decision aids
may meet the inclusion criteria for this review, and we will fully
assess this trial for inclusion when we update the review (Studies
awaiting classification).
Included studies
Four studies, including a total of 1342 participants, met the in-
clusion criteria for this review (Clark 1998; Fiks 2015; van Bragt
2015;Wilson 2010).We have presented a summary of study char-
acteristics in Table 1. We have provided more information about
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each study’s design, setting, inclusion criteria, population and in-
tervention, and risk of bias assessments in the Characteristics of
included studies tables.
Study design and setting
Wilson individually randomised 612 adults with asthma across
five US clinical Kaiser Permanante (KP; a large not-for-profit inte-
grated managed care consortium) sites (Wilson 2010). The three
remaining studies involved children and their families. Clark clus-
ter-randomised 74 US general practice paediatricians, with 637
children enrolled under their care, inMichigan andNewYork State
(Clark 1998). Fiks individually randomised 60 families of children
with asthma across three primary care practices in Philadelphia
(Fiks 2015). Finally, van Bragt randomised five outpatient clinics
in the Netherlands, enrolling a total of 33 children with asthma
(van Bragt 2015).
Population characteristics
Forty-three per cent (266/612) of participants in the only adult
study were male, and investigators reported a mean age of 45.1
to 46.9 years across the three intervention arms (Wilson 2010).
Approximately 60% of participants were Caucasian, 15% Africian
American, and 10% Asian, with the remaining participants from
Hispanic, Pacific Islander, and American Indian ethnic groups.
Approximately 70% of participants reported a household income
greater than $40,000 per year, and more than 95% had completed
at least high school level education. Eighty-four per cent of par-
ticipants were reported to have poorly or very poorly controlled
asthma at baseline, with forced expiratory volume in one second
(FEV1) < 80% predicted in 70% of participants. Approximately
16% were current smokers.
The Clark study reported that 60% (44/74) of included paedia-
tricians were male, as were 70% (471/637) of enrolled children
(Clark 1998). Researchers provided data on an average of 10 chil-
dren per paediatrician (range 1 to 33). Seven per cent of enrolled
children were younger than two years of age, 59% were between
two and seven years, and 34% were 8 to 12 years old. Fifteen per
cent of enrolled children were Latino/Hispanic, and 15% were
Africian American. Study authors provided no details about the
ethnicity of the remaining 70%. Approximately 20% of partic-
ipating families reported a household income less than $20,000
per year, and 16% were below the poverty level of $15,000 an-
nual household income. Almost 90% of parents had at least a
high school level education. Investigators did not report baseline
asthma severity.
Fiks did not report the gender of the 60 paediatric participants
in this trial (Fiks 2015). Children had a mean age of 8.3 years,
47% were black/Africian American, and 42% were white, with
the remainder described as Asian, Hispanic, or other. Seventy-one
per cent of parents had at least some college level education, and
75% were in paid employment. Data show that baseline asthma
severity was mild in 53% of children,moderate in 42%, and severe
in 5%.
Finally, 62% (18/29) of the children included in the last studywere
male, and their mean age was approximately 8.5 years (van Bragt
2015). Ninety-seven per cent of children were Caucisian. Eighty-
seven per cent of families in the intervention arm were reported to
be from a high socioeconomic group, as were 64% in the control
group. Mean FEV1% predicted was > 100% in both groups at
baseline. Data indicate that asthma was uncontrolled (ACQ score
≥ 1) at baseline in 3/15 (20%) in the intervention group and in
6/14 (43%) in the control group.
Inclusion and exclusion criteria
Wilson specifically recruited adults whose asthma was not well
controlled and were therefore likely to have inadequate adherence
to their asthma regimen (Wilson 2010). Eligible patients were
between 18 and 70 years of age. Poorly controlled asthma was
evident in medical records by overuse of reliever medication or
a recent emergency department (ED) visit or hospitalisation for
asthma. Participants were excluded if they had intermittent asthma
or a primary diagnosis of COPD, or were using regular OCSs.
Participants were also excluded if they were already enrolled in an
asthma management programme.
Clark enrolled children aged 1 to 12 years through participat-
ing paediatric general practitioners (Clark 1998). Eligible children
must have had physician-diagnosed asthma and no other chronic
disorders with pulmonary complications, and must have had at
least one emergency medical visit for asthma during the past year.
Fiks recruited children aged 6 to 12 years with persistent asthma
and an English-speaking parent or guardian who had consistent
access to a computer and the Internet (Fiks 2015). Children were
excluded if their asthma was not a primary or current health con-
cern for their parent or guardian, or if they were not taking a “con-
troller medication”.
van Bragt recruited children aged 6 to 12 years with physician-
diagnosed asthma who had used asthmamedication (bronchodila-
tors and/or inhaled corticosteroids (ICSs)) for at least six weeks
over the preceding year (van Bragt 2015). Children were excluded
if they had comorbid conditions that would significantly impact
their health-related quality of life, were not receiving mainstream
education, or had insufficient Dutch language skills.
Interventions and comparisons
Wilson 2010
Group 1. Shared decision-making (SDM)
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Participants received two face-to-face sessions and three phone
calls over nine months. Sessions involved eliciting the patient’s
asthma history, classifying the level of control, and providing
asthma education. In the SDMmodel, this was followed by nego-
tiation of a treatment plan that took into account the participant’s
goals and preferences. Researchers shared with participants a full
list of appropriate guideline-based treatment options for all levels
of asthma severity before arriving at a treatment plan that best
accommodated the participant’s and the care manager’s goals.
Investigators provided a written asthma management and action
plan at the end of the first session and adapted it as required in
subsequent sessions.
Group 2. Clinical decision-making (CDM)
As above for SDM, but instead of a negotiated treatment plan,
the care manager prescribed an appropriate regimen based on the
patient’s level of asthma control and explained this decision to the
patient.
Group 3. Usual care
Usual care at KP is based on a guideline-based stepped-care ap-
proach to pharmacotherapy with the goal of long-term asthma
control.
Intervention fidelity
Sixteen nurses, respiratory therapists, pharmacists, nurse practi-
tioners, and physician assistants were recruited to deliver the in-
tervention. Most were already trained asthma care managers. Re-
searchers scored audiotapes of both sessions for 10% of partici-
pants against a checklist to ensure fidelity to the study protocol.
They also asked participants to report their perceived role in the
treatment decision after session one. The SDM model was based
on “four key defining features described byCharles and colleagues”
(Charles 1997; Charles 1999).
Clark 1998
Group 1. Interactive seminar programme
General practice paediatricians in this group received two interac-
tive face-to-face seminars, each lasting approximately 2.5 hours,
over a two- to three-week period. Seminars were based on the the-
ory of self-regulation, “guiding physicians to examine their own
behaviour and to identify ways that they could develop a better
partnership with their patients”. This included a focus on deriv-
ing information for making therapeutic decisions, creating a sup-
portive atmosphere, reinforcing self-management, giving a view of
the long-term therapeutic plan, and building patients’ confidence
in controlling symptoms and using medicines. Seminars included
brief lectures from respected asthma specialists, a video example,
case studies, and a self-assessment protocol for physicians.
Group 2. Control
General practice paediatricians in this group continued their usual
asthma care practices.
Intervention fidelity
Physicians were asked to rate their own performance through a
survey.Questionswere related not only to prescribing practices but
also to procedures such as encouraging self-management, provid-
ing patient teaching, and exhibiting supportive communication
and behaviour. Investigators collected similar data from patients
and their parents and correlated this information with physicians’
reports, noting a good level of agreement. The trial did not in-
clude an explicit assessment of intervention fidelity and did not
attempt to record or observe physicians interacting with patients
and parents.
Fiks 2015
Group 1. MyAsthma shared decision-making portal
Participants in this group used “MyAsthma”, a shared decision-
making portal linked to their electronic health record. Clinicians
and families had developedMyAsthma with the aim of promoting
SDM. The main features of this online portal included eliciting
parents’ concerns and asthma treatment goals; tracking symptoms
and side effects; providing educational content; and granting ac-
cess to participants’ individual asthma care plans. Families were
prompted to complete a monthly survey, the results of which were
used to provide guideline-based decision support for parents and
clinicians.
Group 2. Control
Participants in this group did not have access to the MyAsthma
portal, but their clinician had access to the decision support system
designed to promote guideline-based asthma care.
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Intervention fidelity
Study staff provided “brief training” to families randomised to
receive the MyAsthma intervention and sent monthly emails to
remind them to complete portal surveys, on which subsequent
decision support was based. Acceptibility of the intervention was
recorded through surveys at baseline, at three months, and at
six months; these surveys included questions about satisfaction
with asthma care. The proportion of participants completing the
monthly portal survey was used as a measure of feasibility.
van Bragt 2015
Group 1. PELICAN online tool
Children in this group used a self-administered online health-re-
lated quality of life instrument, specifically developed for children
aged 6 to 11 years. Children were invited to respond to a series
of questions using a 5-point Likert scale and to choose from a
list of specific asthma problems the ones that may bother them in
their daily life. Children completed the PELICAN tool before each
study visit, and investigators used their answers to guide asthma
management, based on SDM between child, parent, and nurse.
After the first session, researchers produced a written action plan
that would be reviewed at subsequent sessions.
Group 2. Enhanced usual care
Children in this group were assessed every three months. Specific
issues addressed included symptoms, medication use, and expo-
sure to asthma triggers, according to the guidelines of the Dutch
College of General Practitoners. Consultations provided by the
child’s usual general practitioner or nurse typically lasted 10 min-
utes.
Intervention fidelity
Study authors did not describe the procedure used to train children
to use the online tool. Nurses delivering the face-to-face shared
decision-making consultation were trained in the process during a
two-hour meeting before the study began and were monitored for
a fixed number of “feedback/observation moments”. Telephone
support was provided for specific questions.
Outcomes
Clark 1998: physician survey (items related to using clinical prac-
tice methods/medicines, encouraging self-management, and pro-
viding patient teaching and communications); parent interview
form (questions related to symptom status of the child, medicines
prescribed, and use of healthcare services for asthma (ED visits,
hospitalisations, physician office visits);as well as parents’ obser-
vations and opinions of physicians’ teaching and communication
behaviours and other aspects of the clinician-patient interaction).
Data were collected from physicians at baseline, at five months
(“mid-point”), and at one year after the mid-point. Investigators
tracked patient visits over 22 months and collected data from pa-
tients on average two months after their visit.
Fiks 2015: feasibility (assessed as percentage of participants in the
intervention group completing the monthly portal survey); ac-
ceptability of asthma care (measured at six months on an 11-point
Likert scale); clinical outcomes (numbers of asthma ED visits, hos-
pitalisations, and specialist and general practitioner visits over the
six-month study); number of prescriptions assessed through elec-
tronic health records; number of days of missed school (child) or
work (parent) over past month; Parent Patient Activation Measure
(tool that can be used to assess the knowledge, skills, and confi-
dence needed to manage a child’s health care; regarded as a mea-
sure of satisfaction (higher score = higher activation)); Integrated
Therapeutics Group - Child Asthma Short Form (ITG-ASF); and
asthma control test. Families completed surveys at enrolment and
at three and six months.
van Bragt 2015: primary outcome: quality of life (Pediatric Asthma
Quality of Life Questionnaire (PAQLQ)); secondary outcomes:
asthma control (ACQ); symptoms and medication via a diary;
cost-effectiveness; caregiver quality of life (Pediatric Asthma Care-
giver’s Quality of Life Questionnaire (PACQLQ)); process out-
comes. Investigators collected data at three, six, and nine months
after the baseline assessment.
Wilson 2010: primary outcomes: adherence to controller med-
ications; better asthma-related quality of life; and improved
healthcare utilisation; secondary outcomes: short-acting beta-ago-
nist (SABA) use; lung function; and asthma control. Investigators
collected data at 12 and 24 months post randomisation.
Excluded studies
We excluded 11 studies after viewing full texts: Nine stud-
ies tested an intervention that was not focused on improv-
ing shared decision-making (Ford 1996; Gorelick 2006; Moffat
2008; NCT00170248; NCT00214669; Smith 2008; Sockrider
2001; Tapp 2014; Tieffenberg 2000). One was not an RCT
(NCT01522144). Another study recruited a mixed respira-
tory population (Early 2015). In addition, we have listed four
relevant studies as ongoing (Federman 2015; Hoskins 2013;
NCT02516449; Tapp 2011).
Risk of bias in included studies
We have provided a summary of our risk of bias judgements in
Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We considered one study to be at low risk of bias because trial au-
thors described computerised methods of generating the random
sequence and concealing allocation (Wilson 2010). Another study
used minimisation software to generate the random sequence but
did not describe allocation concealment, so we rated risks of bias as
low and unclear, respectively (van Bragt 2015). We rated another
study as having unclear and low risks of bias because it did not
describe random sequence generation but used sealed envelopes
to conceal allocation (Fiks 2015). We rated the remaining study
as having unclear risk of bias for random sequence generation and
high risk of bias for allocation concealment because the method
of selecting participants for inclusion was not well concealed, and
this may have introduced a selection bias (Clark 1998).
Blinding
We considered three studies to be at high risk of bias for both
blinding domains because patients, physicians, or both were aware
of group allocation, and this may have affected how they behaved
and responded during and after the intervention (Fiks 2015; van
Bragt 2015; Wilson 2010). The other included study blinded pa-
tients and parents to physicians’ involvement in the study, so out-
comesmeasured by patients and parents would be at low risk of de-
tection bias, but outcomes rated by physicians would be at higher
risk (Clark 1998). We assessed separately the likelihood that each
outcome would be subject to performance and detection biases
when GRADE ratings were applied.
Incomplete outcome data
Two studies were at low risk of attrition bias because a similar
and low proportion of participants from either group could not
be included in the final analyses (Fiks 2015; Wilson 2010). We
considered the other two studies to be at high risk of attrition bias
because overall dropout was high and numbers randomised and
completed in each group were not reported fully, or because all
dropouts came from the control group (Clark 1998; van Bragt
2015).
Selective reporting
We rated one study as having low risk of reporting bias because it
was prospectively registered and researchers reported all specified
outcomes as planned (van Bragt 2015). We rated three studies as
havinghigh risk of reporting bias; twowere prospectively registered
and the full report did not include data for all planned outcomes
or time points, and one reported some outcomes narratively or
in a way that meant data could not be pooled in a meta-analysis
(Clark 1998; Fiks 2015; Wilson 2010).
Other potential sources of bias
Wedidnot note any additional sources of bias in two studies (Clark
1998; Wilson 2010). In another study, study authors noted: “The
study population was a convenience sample based largely on clin-
ician recommendation and was not designed to be representative
of all children with asthma in the care network”, but it is unclear
whether this introduces bias (Fiks 2015). We rated another study
as having high risk of bias because the 33 children recruited were
significantly fewer than the 170 planned, potentially leading to
underpowered analyses. In addition, groups were not balanced at
baseline for asthma control or for socioeconomic status (van Bragt
2015).
Effects of interventions
See: Summary of findings for the main comparison Shared
decision-making compared with usual care for people with asthma
We did not consider interventions, comparisons, or outcomes re-
ported in the included studies to be sufficiently similar for pooling
to make sense. We present a narrative description of the outcomes
of interest for each included study, structured according to our
prespecified primary and secondary outcomes. When possible, we
present findings from individual studies on forest plots to provide
a visual representation of the effect estimate.
Primary outcomes
Asthma-related quality of life
Three studies reported asthma quality of life.
Fiks reported three subscales of the ITG-ASF (higher score =
poorer quality of life) as change from baseline for 53 participants
but did not report a measure of variance (Fiks 2015). We back-
calculated standard deviations (SDs) from reported P values for
differences between arms. Confidence intervals include no differ-
ences for each of the subscales. We presented results in Analysis
1.2. (very low-quality evidence).
Wilson (a three-arm trial) also reported on the endpoint quality
of life, using the symptoms domain of the mini-AQLQ (Wilson
2010). We have presented SDM versus usual care comparisons in
Analysis 1.3. We back-calculated SDs from the P value given for
the difference (P = 0.0003). Although the mean difference falls
below the minimal clinically important difference (MCID) of 0.5
for this scale, responder analysis demonstrates that significantly
more people experienced an improvement of at least 0.5 units
(odds ratio (OR) 1.90, 95% confidence interval (CI) 1.24 to 2.91;
participants = 371; studies = 1; Analysis 1.1). We have moderate
confidence in these results.
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Of note,Wilson reported that themean difference inmini-AQLQ
symptom score for SMD versus CDM was 0.1 and described this
finding as non-significant. A responder analysis for this compari-
son revealed that the number of people in the CDM group with
improvement greater than 0.5 units was 110/180. If this is used as
the control group, the effect is smaller and the lower confidence
interval shows no difference (OR 1.51, 95% CI 0.97 to 2.34; data
not presented).
van Bragt reported child and parent scores on the AQLQ as me-
dians and interquartile ratios (IQRs) (van Bragt 2015). We noted
baseline imbalances, and although investigators stated in themeth-
ods section that they would adjust for this, it is unclear whether
this was done, as data were not normally distributed. Scores were
slightly higher in the SDM group than in the control group, and
the number of participants was small (6.78 vs 6.5 children (n =
29); 6.96 vs 6.85 parents (n = 25); IQRs between 0.31 and 0.96).
Patient/parent satisfaction
Clark reported parental views on the “demeanour and communi-
cations skills of the paediatrician”, adjusted for clustering, using
a number of different measures, but these investigators presented
results without a measure of variance, so we have not presented
them graphically (Clark 1998). Study authors followed up a to-
tal of 472 parents of enrolled children for this outcome. Parents
in the intervention group were significantly more likely to report
that the paediatrician was reassuring and encouraging; described
as a goal that the child could be fully active; looked into how the
family managed asthma on a day-to-day basis; and gave parents
information to relieve their specific worries and concerns about
asthma (Table 2).
Fiks reported the number of parents who completed the portal
survey for each of the six months of the study and considered this
to be a measure of acceptability of the intervention (Fiks 2015).
It should be noted that parents of children in the control group
did not have access to the portal, and therefore this outcome was
measured only in the SDM group. Of the 30 families randomised
to the intervention group, 17 (57%) completed the survey five or
more times, which was defined as frequent use, and 77% com-
pleted the survey more than once. It was also noted that parents of
children with more severe asthma were more likely to be frequent
users of the portal (75% vs 47% with mild persistent asthma).
Twenty-two out of 24 parents reported that the MyAsthma inter-
ventionmade it easier to care for their childwith asthma, and 10 of
24 parents reported that the portal made it easier to communicate
with their child’s healthcare providers. Six parents reported that
the portal increased their awareness of the importance of asthma
management.
This same study reported “parental activation” using the Parent Pa-
tient Activation Measure. This tool assesses the knowledge, skills,
and confidence needed to manage a child’s health care and could
be regarded as a measure of satisfaction (higher score = higher ac-
tivation). Data showed no significant differences between study
arms; change scores were reported as 2.3 and 2.4 in SDM and
control groups, respectively (P = 0.9).
Medication adherence
Fiks reported the mean number of “controller” medication pre-
scriptions over 26 weeks as 1.1 in the SDM group (n = 26) and
0.7 in the control group (n = 27) (Fiks 2015).
Wilson reported medication adherence for all medications and
for inhaled corticosteroid (ICS) alone as continuous medication
acquisition (CMA) (Wilson 2010). This is calculated as the total
days’ supply acquired in a given year divided by 365 days. Results
suggest that SDM increases CMA when compared with usual care
(Analysis 1.4; all medication: mean difference (MD) 0.21, 95%
CI 0.11 to 0.31; ICS alone: MD 0.22, 95% CI 0.11 to 0.33;
participants = 371; moderate-quality evidence). Our confidence
in this finding was reduced by the potentially indirect nature of
using CMA to measure adherence. The CMA mean difference
between SDM and CDM in the Wilson study was 0.029 for all
medication and 0.017 for ICS alone; these mean differences are
smaller than those for SDM versus usual care but are also reported
as statistically significant (Wilson 2010). Of note, trialists also
collected CMA data at two years and reported that between-group
differences were no longer significant.
CMA findings are supported by an additional metric of the
beclomethasone dipropionate (BDP) equivalent of canisters ac-
quired, which shows an effect in favour of SDM at one year and at
two years, although a smaller difference after two years (data not
shown).
Secondary outcomes
Exacerbations of asthma (leading to a course of oral
corticosteroids or unscheduled visit to a healthcare
professional)
Clark reported mean numbers of ED visits and hospitalisations
per child and showed no clear between-group differences (mean
number of ED visits: SDM = 0.65, usual care = 0.67; hospitalisa-
tions: SDM = 0.081, usual care = 0.076; both P values were ad-
justed for clustering and were reported as non-significant) (Clark
1998).
Fiks reported the mean number of oral corticosteroid (OCS) pre-
scriptions over 26 weeks, without variance, as 0.4 in the SDM
group (n = 26) and 1 in the control group (n = 27) (Fiks 2015).
This study also reported the numbers of children with exacerba-
tions requiring hospital admission, an ED visit, a specialist visit,
and a general practitioner visit. We have presented these data in
Analysis 1.5; all four point estimates favour shared decision-mak-
ing, but confidence intervals are wide, and our confidence in these
findings is low. Finally, study authors reported the change in the
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number of asthma exacerbations, captured by the “Asthma Con-
trol Tool” (a validated instrument in children), as -3.3 in the SDM
group and -1.3 in the control group (25-point scale; P = 0.02).
Wilson reported rates of asthma-related visits in this three-arm
study (Wilson 2010).During year 1, both SDMandCDMgroups
had significantly lower visit rates (1.0/y and 1.1/y) than the usual
care group (1.4/y; P = 0.0161 and 0.0147, respectively).
Asthma control
Fiks reported change in “asthma symptoms while at best” on the
“Asthma Control Tool” as -2.8 in the SDM group and -0.6 in the
control group (P = 0.10), with a lower score indicating less severe
symptoms (Fiks 2015).
vanBragt assessed asthma control using the AsthmaControlQues-
tionnaire (ACQ) and the Asthma Control Test (ACT) and pre-
sented results as medians and IQRs. Baseline imbalances were
notable (ACQ in favour of intervention and ACT in favour of
control), and, as data were not normally distributed, it is unclear
whether scores were adjusted accordingly (van Bragt 2015). This
same trial dichotomised participants into well controlled and not
well controlled (well controlled seen as < 1 on the ACQ and > 22
on the ACT). Study authors detected no between-group differ-
ences, but confidence intervals were wide and the number classi-
fied as ’well controlled’ at baseline was unbalanced (Analysis 1.6;
low-quality evidence).
Wilson reported change from baseline on the Asthma Therapy
Assessment Questionnaire (ATAQ) but did not give any measure
of variance (Wilson 2010). Changes were as follows: -0.8 in the
SDM group, -0.54 in the CDM group, and -0.46 in the usual
care group, with lower scores indicating better control. This same
study used the ATAQ to report the number of people with ’no
asthma problems’ (ATAQ score = 0). We have presented SDM
versus usual care in Analysis 1.6 (moderate-quality evidence); the
odds ratio for the SDM versus CDM comparison shows a smaller
but still significant effect in favour of SDM: 1.6 (1.1 to 2.4, P =
0.0239).
Acceptability/feasibility from the perspective of healthcare
professionals
We did not find any data about this.
Adverse events (all)
None of the included studies measured or reported adverse events.
Subgroup and sensitivity analyses
It was not possible to conduct any of the planned subgroup anal-
yses (age; who the intervention was aimed at; extensiveness of in-
tervention), as we did not perform any meta-analyses. We have
presented a summary of study characteristics in Table 1.
Similarly, it was not possible to test the robustness of study results
by performing sensitivity analyses while excluding unpublished
data and studies at high risk of selection bias.
D I S C U S S I O N
Summary of main results
This review includes four studies of shared decision-making
(SDM), allocating a total of 1342 participants to either SDM in-
terventions or control. Study design, populations, interventions,
comparisons, and outcomes are substantially different between
the four studies. Three studies recruited children with asthma
and their care-givers (Clark 1998; Fiks 2015; van Bragt 2015).
One study recruited adults (Wilson 2010). Asthma severity ranged
from mild to severe. Three studies took place in the United States
(Clark 1998; Fiks 2015;Wilson 2010). One was conducted in the
Netherlands (van Bragt 2015). Trial duration was between six and
24 months, and outcomes were measured at a range of time points
from six months to two years.
All studies were conducted in a primary care or outpatient set-
ting, and the intervention was delivered in various ways, either to
participants directly or to healthcare professionals. Two studies in
children used an online portal to elicit key asthma management
concerns and goals; this was followed by face-to-face discussions
with a healthcare professional based on shared decision principles
(Fiks 2015; van Bragt 2015). Clark provided seminars aimed at
developing skills in SDM among paediatric general practitioners,
who in turn enrolled their patients into the study (Clark 1998).
Wilson provided to participants a mixture of face-to-face discus-
sions and telephone calls with personnel trained in SDMor in clin-
ical decision-making (CDM) (Wilson 2010). The duration and
content of interventions varied, but SDM was a key component
of the intervention provided in all included studies. Owing to the
nature of the intervention, it was not possible to blind participants
or trial personnel to group allocation. Review authors considered
the impact of the lack of blinding on an outcome-specific basis
when assigning GRADE ratings.
Meta-analysis of results was not possible owing to the small num-
ber of heterogenous trials included. Three studies used different
tools to assess asthma-related quality of life and reported inconsis-
tent results. Fiks conducted a study in children that compared an
SDM online portal versus guideline-based care presented in sub-
scales of the Integrated Therapeutics Group - Child Asthma Short
Form (ITG-ASF) and did not demonstrate between-group differ-
ences, although confidence intervals were wide (Fiks 2015). Simi-
larly, van Bragt conducted a study in children using an online tool
and found little difference between SDM and control groups (van
Bragt 2015). Wilson completed a study in adults involving face-
to-face and telephone consultations and identified benefit of SDM
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over usual care, using the mini-Asthma Quality of Life Question-
naire (AQLQ) symptom scale (Wilson 2010). This benefit was
confirmed by a responder analysis.
Two studies reported patient/parent satisfaction, or proxy mea-
sures. In a cluster-randomised trial in which SDM training was
provided to physicians, Clark reported that parents of children
in the intervention group were significantly more likely to report
satisfaction with the paediatrician (Clark 1998). Fiks reported
“parental activation” using the Parent Patient Activation Measure
but noted no significant differences between study arms (Fiks
2015).
Two studies reported medication adherence. Fiks indicated that
the mean number of controller medication prescriptions over 26
weeks was greater in the SDMgroup (Fiks 2015).Wilson reported
medication adherence for all medications and for inhaled corticos-
teroids (ICSs) alone as continuous medication acquisition (CMA)
(Wilson 2010). Results suggest that SDM increases CMA when
compared with usual care, but that differences are lessened over
time.
Of our secondary outcomes, study authors reported only exac-
erbations and asthma control. Three studies reported exacerba-
tions.Mean numbers of emergency department (ED) visits and
hospitalisations per child reported byClark showno clear between-
group differences (Clark 1998). Fiks indicated that themean num-
ber of oral corticosteroid (OCS) prescriptions over 26 weeks was
reduced in the SDM group compared with the control group
(Fiks 2015). This study also reported the number of children with
exacerbations requiring an unscheduled visit or hospital admis-
sion; point estimates favoured SDM, but confidence intervals were
wide. Wilson reported rates of asthma-related visits and indicated
that the SDM group had significantly lower visit rates than the
usual care group (Wilson 2010). Three studies reported asthma
control. Changes in “asthma symptoms while at best” on the
“Asthma Control Tool” as reported by Fiks were noted to be lower
in the SDMgroup than in the control group (Fiks 2015). vanBragt
assessed asthma control using the Asthma Control Questionnaire
(ACQ) and the Asthma Control Test (ACT) and dichotomised
participants into two groups: well controlled and not well con-
trolled (van Bragt 2015). Researchers reported no between-group
differences, but confidence intervals were wide. One study used
the Asthma Therapy Assessment Questionnaire (ATAQ) to report
the number of people with ’no asthma problems’ (ATAQ score =
0) and described benefit of SDM over control (Wilson 2010).
Overall completeness and applicability of
evidence
Only four studies met the inclusion criteria for this review, thus
the body of evidence available from randomised controlled tri-
als (RCTs) is limited at this time. Substantial differences in study
design, populations, interventions, comparisons, and outcomes
prevent overall conclusions. Although we identified several ran-
domised trials in asthma that included an element of SDM, we
considered this to be only one element of a broader intervention
and thus excluded these studies (see Characteristics of excluded
studies). This may have resulted in loss of useful information, but
we judged it would not have been possible to confidently ascribe
any clinical benefit to SDM in the context of a much broader in-
tervention. The small number of trials identified also meant that
no subgroup analysis could be performed as planned on the basis
of content, intensiveness, or duration of the intervention; these
are all likely to be important effect modifiers.
Whether or not the intervention was delivered with a high level
of fidelity is also an important consideration when outcomes of
SDM interventions are assessed. All four studies attempted to cap-
ture fidelity or intervention adherence using different approaches.
Investigators in two studies reported observing or recording trial
staff to ensure that the intervention was delivered as planned (van
Bragt 2015; Wilson 2010). Investigators in another trial asked
physicians, who were the primary recipients of the intervention,
to rate their own performance, which was reported as having a
high level of correlation with their patients’ reports (Clark 1998).
However, this trial report did not describe attempting to observe
or record physicians while interacting with patients. Families re-
cruited in another study received “brief training” by study staff on
use of the online portal and recorded acceptability through surveys
that included questions about satisfaction with asthma care (Fiks
2015). The proportion of participants completing the monthly
portal survey was used as a measure of feasibility, and trialists re-
ported that 77% of parents completed the survey at least twice, out
of a possible six times. Fifty-seven per cent completed the survey
five or more times.
Although adverse eventsmight not be anticipated in trials of SDM,
none of the included studies set out to systematically measure and
report this outcome; this is another limitation of the evidence pre-
sented. Another important gap is the fact that none of the in-
cluded studies focused on adolescents. Adolescents are at higher
risk of poor asthma outcomes, including death, when compared
with younger children (Akinbami 2002; Akinbami 2006). Asthma
management during adolescencemay require particularly high lev-
els of trust and good communication between care providers and
patients; therefore SDM interventions have the potential for sub-
stantial impact (de Benedictis 2007).
Three out of the four included studies were conducted in the
United States, and the fourth in another high-income setting (the
Netherlands). This may limit applicability of findings to other
healthcare systems facing greater resource constraints and with dif-
ferent cultural approaches to the relationship between healthcare
professionals and patients. Cost-effectiveness is also not addressed
in this review nor in the included studies. Evidence suggests that
SDM interventions may not be cost-neutral, so studies including
an economic evaluation would be a useful addition to the evidence
base (Veroff 2013).
We also noted that baseline asthma severity and control varied
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between studies (e.g. most participants in the Wilson study had
poorly controlled asthma, whereas mean ACQ score in the van
Bragt trial was < 1, suggesting overall good asthma control; Fiks
reported that a largemajority of participants hadmild or moderate
asthma) (Fiks 2015; van Bragt 2015; Wilson 2010). A possible di-
rection for future research would be to investigate whether people
with more or less severe asthma benefit more or less from SDM
than those given usual care. The limited number of studies in this
review means that we cannot currently comment on this. A fur-
ther consideration is that those who agree to participate in SDM
trials and those who adhere to the trial protocol once recruited
may differ substantially from those not recruited. This may limit
generalisability of findings from such trials to the wider asthma
population.
Finally, choice of control group and treatment setting may have
an impact on whether an SDM intervention leads to improve-
ment in asthma outcomes. Usual care practices vary widely be-
tween settings; some may include elements of SDM routinely,
which would likely limit differences seen between intervention
and control groups. A thorough description of routine practices is
important for an understanding of local applicability of findings
from individual trials.
Quality of the evidence
We were not able to apply GRADE to all outcomes as planned
because we had no pooled data for some analyses, including pa-
tient/parent satisfaction; acceptability from the perspective of the
healthcare professional; and adverse events. When we were able
to make a judgement, our confidence ranged from very low to
moderate. We downgraded subjective outcomes (quality of life
and asthma control) owing to inherent risk of bias introduced by
unblinded trials, although it is difficult to conceive a trial of SDM
in which effective participant and personnel blinding would be
possible. We did not consider the open-label design of trials to
pose such a threat to outcomes such as medication adherence and
exacerbations.
We had concerns about indirectness in trials that reported subscale
scores from a quality of life questionnaire, rather than total scores,
and we downgraded evidence for this reason. We also downgraded
medication adherence evidence, as we judged continuous medica-
tion acquisition to be a proxy measure of adherence that may over-
estimate true adherence.We noted that imprecision was a problem
for several outcomes, including quality of life, exacerbations, and
asthma control, with confidence intervals including the possibility
of both harm and benefit from the intervention.
We did not detect statistical heterogeneity because we did not pool
studies owing to differences in study design, outcomes reported,
or both (i.e. high clinical heterogeneity); therefore we ran no tests
for heterogeneity. We have reported findings narratively when rel-
evant. We did not suspect publication bias but did not include
sufficient studies to produce a funnel plot.
Potential biases in the review process
We carried out the review according to methods provided in the
published protocol and detailed deviations from the protocol in
the Differences between protocol and review section (Kew 2016).
As planned, two review authors independently screened search
results and resolved discrepancies by discussion.We did not restrict
the search by date or by language. At least two review authors
extracted all study characteristics and numerical data and resolved
discrepancies through discussion. The same was true for risk of
bias ratings and GRADE ratings, for which a third person was
consulted as required to resolve disagreements. Two additional
review authors joined the team to complete the update (RN and
KA). Insufficient data prevented completion of planned meta-
analyses and subgroup and sensitivity analyses.
Agreements and disagreements with other
studies or reviews
Toour knowledge, this is the first systematic review that synthesises
evidence from RCTs on SDM in asthma. Several other systematic
reviews have explored the association between SDM and health
outcomes and behaviours across a range of medical conditions. A
consistent theme across these reviews, in keeping with the present
review, is the difficulty of meaningfully combining evidence from
the wide range of trials taking place in this field.
A recent review, including 39 studies, most of which were obser-
vational, found that although affective-cognitive outcomes may
be favourable if participants perceive that SDM has occurred,
evidence linking empirical measures of SDM to health and be-
havioural outcomes is lacking (Shay 2015). Joosten and colleagues
identified 11 RCTs of SDM involving adults across various medi-
cal conditions (Joosten 2008). Although these review authors con-
cluded that SDM may be beneficial, especially in the context of
chronic illness, they noted that evidence fromRCTs regarding im-
pact on health outcomes is lacking.
A 2015 review of SDM in paediatrics identified 61 studies, most
of which were observational in design, and focused on satisfaction,
decisional conflict, and knowledge, rather than health outcomes.
Only 15 studies could be meta-analysed, and review authors con-
cluded that SDM interventions in paediatrics remain poorly de-
fined, but limited available evidence suggests that SDM may re-
duce decisional conflict,and improve parent knowledge (Wyatt
2015). Durand and colleagues in their systematic review specifi-
cally addressed whether SDM interventions can reduce health in-
equalities (Durand 2014). Review authors concluded following a
narrative synthesis of evidence that SDM interventions may be
more beneficial for those from disadvantaged groups, but confi-
dence in their findings was reduced by between-study heterogene-
ity.
Légaré and colleagues synthesised evidence related to effectiveness
of interventions aimed at patients or healthcare professionals to
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improve SDM (Légaré 2014). They identified 39 studies, 38 of
which were RCTs. Despite the large number of studies included,
review authors were not able to conclude whether interventions
to improve adoption of SDM are effective, although they suggest
that targeting both patients and healthcare professionals is likely
to be more effective than targeting just one or the other.
Reviews investigating the role of SDM in other specific conditions
have demonstrated benefit; for example, one trial addressed SDM
in the context of antibiotic prescribing for acute respiratory illness,
and another investigated SDM for people with dementia (Coxeter
2015; Daly 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We have presented findings from four heterogeneous studies of
shared decision-making in asthma. Substantial differences between
studies mean that we cannot form overall conclusions. Individual
studies have demonstrated some benefits of shared decision-mak-
ing over control, including quality of life; patient and parent satis-
faction; adherence to prescribed medication; reduction in asthma-
related visits/exacerbations; and improved asthma control (Clark
1998; Wilson 2010). Our confidence in these findings from indi-
vidual studies ranges from moderate to very low, primarily owing
to concerns about performance and detection bias, indirectness,
and imprecision. It is important to note that studies did not mea-
sure or report adverse events, so no information on harmful effects
of shared decision-making is available.
Implications for research
At this time, the body of evidence from randomised controlled
trials of shared decision-making is limited. Future trials should
be adequately powered and of sufficient duration to detect differ-
ences in patient-important outcomes such as exacerbations and
hospitalisations. We recommend use of core asthma outcomes and
validated scales when possible and urge that the study population
should be clearly characterised. Three of the four studies identified
were conducted in theUnited States, and the fourth in theNether-
lands; future studies conducted in lower-income settings would be
of interest. Adverse events should be systematically recorded, even
if none are anticipated. Adolescents have not been represented in
the studies identified to date and should be considered for future
trials. Economic evaluations of future interventions could be con-
sidered, and trialists should seek to explicitly measure and report
intervention fidelity.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Clark 1998
Methods Study design: parallel, open-label, cluster RCT
Length of observation: 22 months
Setting: 74 general practices in Michigan and New York, USA
Participants Population: 74 physicians were randomised and 69 completed the trial. It is not clear
how many were randomised to each group, but the study states that 637 children were
recruited in total, and outcome data were available for 472
Baseline characteristics
Baseline data were reported for the whole population rather than for each group. 60%
of physicians and 70% of children were male. Physician and child ages were reported in
brackets rather than as a mean per group. 30% of families were Latino/Hispanic (15%)
or African American (15%)
Inclusion criteria: Physician criteria: primary specialty of general paediatrics; licensed
no earlier than 1960; providing direct patient care; if board-specialised, certified only in
paediatrics; willing to take part in the interactive seminar if randomised to the treatment
group. Child criteria: 1 to 12 years of age; diagnosis of asthma made by a physician;
no other chronic disorders with pulmonary complications; at least 1 emergency medical
visit for asthma in the previous year. An emergency visit was a hospitalisation, emer-
gency department (ED) visit, or physician office visit on an emergency basis defined as
administration of epinephrine subcutaneously or bronchodilators by aerosol
Exclusion criteria: none in addition to inclusion criteria
Interventions Intervention: shared decision-making seminars for clinicians
Interactive seminar based on self-regulation theory to guide physicians in NAEPP care
and to engage in interactive conversations with patients to derive information formaking
therapeutic decisions, create a supportive atmosphere, reinforce self-management, give
a view of the long-term therapeutic plan, and build patients’ confidence in controlling
symptoms and using medicines. Materials included brief lectures from respected asthma
specialists; a video depicting effective clinician teaching and communications behaviour;
case studies presenting troublesome clinical problems; a protocol by which physicians
could assess their own behaviour regarding patient communications; and review of mes-
sages to communicate and materials to use when teaching patients
Resources: The seminar comprised 2 face-to-face group meetings, each lasting 2 ½ hours,
held over a 2- to 3-week period
Control: usual care
Physicians in the control group were randomly assigned a date corresponding to 1 of the
3 seminar time points, to determine when follow-up interviews of their patients should
begin
Outcomes Physician survey (items related to using clinical practice methods/medicines, encourag-
ing self-management, and providing patient teaching and communications). Analysis
of data illustrated close correlation between physician and parent descriptions of be-
haviour. Questions on the parent interview form related to symptom status of the child,
medicines prescribed, use of healthcare services for asthma (ED visits, hospitalisations,
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Clark 1998 (Continued)
physician office visits), parents’ observations and opinions of physicians’ teaching and
communications behaviours, other aspects of the clinician-patient interaction
Notes Trial registration: not reported
Funding: supported by MD/Family Partnership - Education in Asthma Management
grant number HL-44976 from the Lung Division of the National Heart, Lung, and
Blood Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized, controlled study design” but
no description of how this was done
Allocation concealment (selection bias) High risk “Names of patients meeting criteria were
selected by the investigators at random
from the roster provided by physicians”,
which may have introduced recruitment
bias within practices, even if practices
were themselves randomised adequately to
groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients and their parents were blind to
physicians’ involvement in the interven-
tion.”
“A potential source of bias in the study was
that physicians would give positive reports
of their behavior to be consistent with good
clinical and communications practices. To
guard against such bias, data were collected
from parents of patients regarding physi-
cian behavior as a means of corroborating
physician reports.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Patients and parents were blind so out-
comesmeasured by them can be considered
low risk of bias. Outcomes measured or
self-assessed by the physicians taking part
in the study are at high risk of detection
bias.”
“A potential source of bias in the study was
that physicians would give positive reports
of their behavior to be consistent with good
clinical and communications practices. To
guard against such bias, data were collected
from parents of patients regarding physi-
cian behavior as a means of corroborating
physician reports.”
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Patients and parents were blinded to their
physician’s participation in the interven-
tion. Depends who is reporting the out-
come, and to whom. Will be assessed sep-
arately when GRADE is applied
Incomplete outcome data (attrition bias)
All outcomes
High risk “Data were collected from physicians at
baseline, and 69 (93%) provided follow-
up data 5 months after the program. Data
were also collected from 637 of their pa-
tients at baseline, and in a 22-month win-
dow after the intervention, 472 (74%) of
this number provided follow-up data.” Un-
clear how many were randomised to each
group and whether dropout was balanced,
but nonetheless quite high attrition overall
Selective reporting (reporting bias) High risk Study does not report methods fully, for ex-
ample, number of people assigned to each
group and participant flow. In terms of
data, uncertainty regarding the number of
participants per group means that data are
difficult to analyse reliably in meta-analy-
ses. Some data relevant to this review are
presented narratively. We did not identify
a study protocol or trial registration
Other bias Low risk None noted
Fiks 2015
Methods Study design: parallel, individually randomised, open-label RCT
Length of observation: 6 months
Setting: 3 primary care practices (1 urban, 2 suburban) in Philadephia, USA
Participants Population: 60 families were randomised to the online portal for SDM (30) or to the
control group (30)
Baseline characteristics
Mean age was 8.3 years (SD 1.9) in the intervention group and 8.2 years (SD 1.9) in
the control group. 43% of the intervention group and 40% of the control group were
white. In the intervention group, 60% had mild asthma, 37% moderate, and 3% severe.
In the control group, 47% had mild asthma, 47% moderate, and 6% severe
Inclusion criteria: Eligible participants were children aged 6 to 12 years with persistent
asthma who received care at a study site, along with their parent or legal guardian.
We enrolled English-speaking parents/guardians who served as the primary member of
their household involved in communicating with the doctor’s office and had consistent
computer and Internet access
Exclusion criteria: At clinicians’ discretion, parents of children whose asthma was not
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a primary or current health concern were excluded, as were those not currently taking a
controller medication
Interventions Intervention: shared decision-making portal
MyAsthma, developed with input from families and clinicians with the goal of fostering
ongoing SDM, provided decision support to both clinicians and parents. The clinician
interface appeared in the electronic health record (EHR), and the parent interface ap-
peared within MyChart, the EHR vendor’s patient portal. Features include identifica-
tion of parents’ concerns and goals for asthma treatment; monthly symptom tracking,
drug side effects, goal progress; educational content; and asthma care plan. Parents were
encouraged via email to complete monthly portal surveys. Answers informed guideline-
based decision support for parents and clinicians, directing them to speak to one another
if asthma was not well controlled, or if side effects occurred, or to continue current
therapy
Control: usual care + decision support
Families in the control group did not have access to the portal; however, clinicians caring
for control group children had access to a clinician-focused decision support system
proven effective in fostering guideline-based care
Outcomes Families completed surveys at enrolment and at 3 and 6months. Feasibility assessed as %
of participants in intervention group completing themonthly portal survey. Acceptability
of asthma care measured at 6 months on 11-point Likert scale. Clinical outcomes were
numbers of asthma ED visits, hospitalisations, and specialist and GP visits over the
6-month study (parental report validated when possible by chart review); number of
prescriptions assessed through EHR; and number of days ofmissed school (child) or work
(parent) over past month. Parent Patient Activation Measure. Integrated Therapeutics
Group - Child Asthma Short Form (ITG-ASF) as quality of life measure. ACT as control
measure
Notes Trial registration: NCT01715389
Funding: supported by the Chair’s Initiative Grant and the William Wikoff Smith
Endowed Chair in Pediatric Genomics from Children’s Hospital of Philadelphia, and by
award number K23HD059919 from the Eunice Kennedy Shriver National Institute of
Child Health and Human Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”A randomization sequence was generated
by the study coordinator (SLM). Random-
ization was stratified by practice and by
whether the child had mild or moderate
versus severe persistent asthma.“
Allocation concealment (selection bias) Low risk ”Sealed envelopes were used to ensure
blinding of study staff to treatment condi-
tion before enrolment and randomization.
“
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Parents either had access to the portal or
not so it was not possible to blind them
to treatment allocation. This knowledge
may have affected clinician and parent be-
haviour during the study and potentially
biased outcomes.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were generally parent rated,
which would introduce high risk of detec-
tion bias. Resource use outcomes and pre-
scription refills would be less subject to de-
tection biases
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 families in the intervention group (13.
3%) and 3 in the control group (10%)
could not be reached via phone or email.
These families were not included in the
analysis, but dropout was judged to be low
andbalanced enough that outcomes are un-
likely to have been biased
Selective reporting (reporting bias) High risk Some outcomes listed in the protocol that
were of interest to this review were not fully
reported in the paper or on clinicaltrials.gov
(e.g. satisfaction with asthma care between
groups, total scores on the ITG-ASF and
ACT)
Other bias Unclear risk Study authors noted: “The study popula-
tionwas a convenience sample based largely
on clinician recommendation and was not
designed to be representative of all children
with asthma in the care network.”This does
not necessarily introduce bias
van Bragt 2015
Methods Study design: parallel, cluster-randomised, single-blind RCT
Acronym: PELICAN
Length of observation: 9 months
Setting: 5 outpatient clinics in Holland
Participants Population: 33 children were randomised within the 5 clusters to the intervention group
(15) or the control group (18)
Baseline characteristics
66.7% of the intervention group and 57.1% of the control group were male. Mean age
was 8.4 years (SD 1.7) in the intervention group and 8.7 years (SD 1.7) in the control
group. 93.3% of the intervention group and 100% of the control group were white. In
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the intervention group, mean FEV1 was 111%; 80% were on ICS; mean PAQLQ was 6.
35 (1.17); and ACQ 0.5 (0.6). In the control group, mean FEV1 was 101%; 57% were
on ICS; mean PAQLQ was 6.02 (0.89); and ACQ 0.8 (1.4)
Inclusion criteria: Children had physician-diagnosed asthma, were 6 to 12 years of age,
and used asthma medication (i.e. bronchodilators and/or inhaled corticosteroids) for at
least 6 weeks during the previous year
Exclusion criteria: comorbid conditions that significantly influence health-related qual-
ity of life, not able to attend a regular school class (as an indicator of normal intelligence)
, and insufficient skills in speaking and/or reading the Dutch language
Interventions Intervention: shared decision-making online tool
Nurse-led patient-centred care via an online tool. First, children completed the PAQLQ
and selected 1 to 3 personal asthma problems, which were forwarded to the nurse. Then
at the consultation, the nurse discussed with the child and parent which problem to
prioritise, discussed details of the problem and chose a treatment goal through shared
decision-making, formulated a SMART goal (specific, measurable, acceptable, realistic,
and time-bound), brainstormed solutions together and documented an action plan,
discussed results at the next visit, and repeated if necessary. Nurses were trained in the
process during a 2-hour meeting before the study
Control: enhanced usual care
Besides usual care, the intervention group also received recommendations based on the
Pelican outcome by a practice nurse. Described as enhanced usual care as seen more
regularly than would be the case in practice
Outcomes Primary: quality of life (PAQLQ). Secondary: asthma control (ACQ), symptoms and
medication via a diary, cost-effectiveness, caregiver quality of life (PACQLQ), process
outcomes
Notes Trial registration: NCT01109745
Funding: Dutch Lung Foundation (previously Dutch Asthma Foundation), NutsOhra
foundation, and a grant from the Nijmegen Centre of Evidence-Based Practice (Rad-
boudUMC grant)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “assigned children…in a 1:1 ratio using
minimization software (Minim) that forced
a balance between study arms for age (6-
8 vs. 9-11 years old) and asthma control
(ACQ score <1 vs greater than or equal to
1)”
Allocation concealment (selection bias) Unclear risk Not described but states that individual
practices managed allocation to groups,
which may not have adequately controlled
for selection biases
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Children, parents, and nurses were aware
of treatment allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “This was a single-blinded study. The anal-
yses presented in this manuscript were
based on blinded data. The study code was
broken after the analyses were concluded.
” Study does not specify who was blinded.
Outcome assessment and several outcomes
were patient-rated, which would introduce
high risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Protocol states: “The primary analysis is an
intention-to-treat analysis, however both
explanatory and intention-to-treat analyses
will be performed.”
“A total of 33 children started with the
study, 15 in the intervention group and 18
in the usual care group. One child was lost
to follow-up during the study and three
children had too many missing data of the
primary outcome, leaving 29 children for
the analysis.” All dropouts were from the
usual care group
Selective reporting (reporting bias) Low risk Outcomes relative to the review that were
defined in the trial registration were re-
ported but could not be included in meta-
analyses owing to non-parametric methods
Other bias High risk The 33 children recruited were signifi-
cantly fewer than the 170 planned, which
(1) meant the study was underpowered and
(2) may reflect the feasibility of the inter-
vention
“112 general practices was invited to par-
ticipate of which 28 practices did not re-
spond and 73 other practices refused par-
ticipation for reasons such as lack of time,
participation in other research projects, too
few pediatric asthma patients or no affinity.
Of the 11 practices that decided on partic-
ipation, two practices were withdrawn due
to lack of sufficient participants.”
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Methods Study design: parallel, individually randomised, open-label RCT
Acronym: BOAT
Length of observation: 52 weeks and 104 weeks
Setting: 5 clinical Kaiser Permanante (a not-for-profit health plan) sites in the USA
Participants Population: 612 adults were randomised to a shared decision-making intervention (204)
, clinical decision-making (204), or a usual care group (204)
Baseline characteristics
43.6% of the SDM group was male, 44.1% of the CDM group, and 42.6% of the usual
care group. Mean age was 45.7 (SD 13.3) in the SDM group, 46.9 (SD 12.1) in the
CDM group, and 45.1 (SD 12.4) in the usual care group. Most participants were white
(62.8% SDM, 60.8% CDM, 62.3% usual care). Most participants’ asthma symptoms
were poorly or very poorly controlled (85.8% SDM, 82.9 CDM, 83.2 usual care). Other
characteristics presented included education level, family income, smoking, controller
medication use, recent hospitalisation, symptom frequency, and categories of FEV1 %
predicted.
Inclusion criteria: patients whose asthma was not well controlled, and whose adherence
to their asthma regimen was likely to be inadequate. KP members, aged 18 to 70 years,
with evidence suggestive of poorly controlled asthma, were identified at 5 clinical sites
using computerised records of overuse of rescue medications (a controller/[controller +
rescue medication] ratio < 0.5 and at least 3 beta-agonist dispensings in the past year) or
a recent asthma-related ED visit or hospitalisation
Exclusion criteria: intermittent asthma (brief exacerbations or symptoms less than once/
week), primary diagnosis of chronic obstructive pulmonary disease or emphysema, in-
sufficient pulmonary function reversibility (for ex-/current smokers and those without
regular controller use), regular use of oral corticosteroids, current asthma care manage-
ment
Interventions Intervention: shared decision-making
Sessions followed the same structure as clinical decision-making but with the following
added: description of SDM approach, identification and summary of patient goals and
preferences, discussion of options and relative merits in terms of patients’ goals and
preferences, and negotiation of a treatment decision. Five sessions; 2 face-to-face and
3 over the phone at 3, 6, and 9 months. Intervention delivered to participants by 16
nurses, respiratory therapists, pharmacists, nurse practitioners, and physicians’ assistants,
most of whom were already asthma care managers. Specific training in shared decision-
making was provided
Control 1: clinical decision-making
Sessions included the following: building rapport, schedule for sessions, symptom/med-
ication/triggers assessed, asthma understanding assessed and improved, spirometry re-
viewed, asthma severity and control determined using GINA, adherence problems ad-
dressed, new regimen recommended based on guidelines, prescription, action plan, in-
haler technique instruction and asthma diary given, follow-up appointment set. Five
sessions; 2 face-to-face and 3 over the phone at 3, 6, and 9 months. Intervention deliv-
ered to participants by 16 nurses, respiratory therapists, pharmacists, nurse practitioners,
and physicians’ assistants, most of whom were already asthma care managers. Specific
training in clinical decision-making was provided
Control 2: usual care
Usual care based on a stepped-care approach to pharmacotherapy with the aim of long-
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Wilson 2010 (Continued)
term asthma control, as recommended by the National Asthma Education Prevention
Program’s Expert Panel Report 2. At some sites, clinicians had the option to refer patients
to an asthma care management program similar to but less structured than the clinician
decision-making intervention
Outcomes Primary: adherence to controller medications, better asthma-related quality of life, lower
health care utilisation for acute symptoms than among patients who received usual care
(no asthma care management). Secondary: short-acting beta-agonist (SABA) use, lung
function, asthma control
Notes Trial registration: NCT00149526; NCT00217945
Funding: supported by National Institutes of Health grants R01 HL69358 and R18
HL67092
Notes:Adherencewasmeasuredusing a continuousmedication acquisition (CMA) index
for each year, calculated as the total days’ supply acquired in a given year divided by 365
days (30-32). The index represents the proportion of the prescribed medication supply
acquired by the patient during each 365-day period, and may potentially overestimate,
but not underestimate, actual use
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-based adaptive randomiza-
tion algorithm was used to ensure conceal-
ment from randomization staff and bet-
ter-than-chance balance among the three
groups on age (18-34, 35-50, and 51-70
yr), sex, race/ethnicity, hospitalisation in
the prior two years (yes/no), and frequency
of asthma controller use in the past week
(none,1-3, ≥4 d).”
Allocation concealment (selection bias) Low risk “computer-based adaptive randomization
algorithm was used to ensure concealment
from randomization staff ”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study investigators and participants could
not be kept blind to treatment allocation
owing to the nature of the interventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Most outcomes would be subject to some
form of detection bias by knowledge of
treatment allocation, particularly self-rated
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar proportions of participants in each
group were followed up at 12 months (89.
2% in the SDMgroup, 88.2% in theCDM
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Wilson 2010 (Continued)
group, and 92.6% in the usual care group).
Attendance was similar in SDM and CDM
groups for all time points except 9 months,
where fewer people in the CDM group
(59.3%) than the SDM group (75.5%) at-
tended. It is assumed that attendance at the
session resulted in gathering of appropriate
outcome data at this time point
Selective reporting (reporting bias) High risk Several outcomes are not reported fully for
year 2 (including adherence and asthma
control), and only results for the symptom
subscale are given for the quality of lifemea-
sure, rather than the total score
Other bias Low risk None noted
ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; CDM: clinician decision-making; CMA: continuous medication
acquisition; ED: emergency department; EHR: electronic health record; FEV1: forced expiratory volume in one second; GINA:
Global Initiative for Asthma; GP: general practitioner; ICS: inhaled corticosteroid; ITG-AST: Integrated Therapeutics Group -
Child Asthma Short Form; NAEPP: National Asthma Education and Prevention Program; PACQLQ: Pediatric Asthma Caregiver’s
Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; RCT: randomised controlled trial; SD:
standard deviation; SDM: shared decision-making; SMART: specific, measurable, acceptable, realistic, and time-bound (goal).
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Early 2015 Population does not match the inclusion criteria: mixed respiratory population; only 17% had asthma and results
are not given separately
Ford 1996 Intervention does not match the inclusion criteria: Focus is asthma education, self-management, and empower-
ment, rather than shared decision-making
Gorelick 2006 Intervention does not match the inclusion criteria: case management/discharge planning from emergency de-
partment. Emphasis is not on shared decision-making
Moffat 2008 Intervention does not match the inclusion criteria: Main emphasis is on communication skills. Not enough
information about the intervention to include confidently (only abstracts, no full publication identified)
NCT00170248 Intervention does not match the inclusion criteria: Focus is on supporting physicians’ decisions, not on sharing
decisions with patients
36Shared decision-making for people with asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
NCT00214669 Intervention does not match inclusion criteria; broad intervention in which shared decision-making was not the
primary focus
NCT01522144 Not an RCT: single group assignment
Smith 2008 Intervention does not match the inclusion criteria: patient-centred education following ED visit, not decision-
making
Sockrider 2001 Intervention does not match the inclusion criteria: video to educate asthma families to follow an action plan.
Some emphasis on communication but not strictly on shared decision-making with a clinician
Tapp 2014 Intervention does not match the inclusion criteria: testing different methods of disseminating a shared decision-
making intervention, rather than assessing whether it works
Tieffenberg 2000 Intervention does not match the inclusion criteria: child-centred care and empowerment to self-manage asthma,
not shared decision-making
ED: emergency department; RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Gagné 2017
Methods Parallel randomised controlled trial
Participants Convenience sample of participants 18 to 65 years, with diagnosis of mild to severe asthma, and prescribed inhaled
corticosteroids, alone or in combination with long-acting β2-agonists
Interventions Asthma eduction plus decision aid vs asthma education alone
Outcomes Knowledge of asthma; decisional conflict; appropriate use of asthma pharmacotherapy; asthma control
Notes Funding: Principal investigator and co-investigator received a grant from the Allergy, Genes and Environment Net-
work for funding of the research (reference number for the project: 11CKT2). Funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript
Publication: peer-reviewed journal article
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Characteristics of ongoing studies [ordered by study ID]
Federman 2015
Trial name or title Rationale and design of a comparative effectiveness trial of home- and clinic-based self-management support
coaching for older adults with asthma
Methods Pragmatic randomised controlled trial with 3 arms
Participants 425 adults with asthma aged ≥ 60, based in New York
Interventions 1. Intervention delivered in primary care
2. Intervention delivered at home
3. Usual care
“In the intervention, care coaches use a novel screening tool to identify the specific barriers to asthma control
and self-management they experience. Once identified, the coach and patient choose from a menu of actions
to address it. The intervention emphasizes efficiency, flexibility, shared decision making and goal setting,
communication strategies appropriate for individuals with limited cognition and literacy skills, and ongoing
reinforcement and support. Additionally, we introduced asthma-specific enhancements to the electronic health
records of all participating clinical practices, including an asthma severity assessment, clinical decision support,
and a patient-tailored asthma action plan.”
Outcomes Patients will be followed for 12 months and interviewed at baseline, and at 3, 6, and 12 months; data on
emergency department visits and hospitalisations will be obtained through the New York State Statewide
Planning and Research Cooperative System
Starting date Unclear
Contact information Alex D Federman - Division of General Internal Medicine, Icahn School of Medicine at Mount SInai, New
York
Notes
Hoskins 2013
Trial name or title Goal-setting intervention in patients with active asthma
Methods Two-armed, single-blind, multi-centre, cluster-randomised controlled feasibility trial
Participants Planned recruitment: 80
Primary care patients with active asthma from at least 8 practices across 2 health boards in Scotland (10
patients per practice, resulting in ~40 in each arm)
Interventions “Patients in the intervention arm will be asked to complete a novel goal-setting tool immediately prior to an
asthma review consultation. This will be used to underpin a focused discussion about their goals during the
asthma review. A tailored management plan will then be negotiated to facilitate achieving their prioritised
goals. Patients in the control arm will receive a usual care guideline-based review of asthma.”
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Hoskins 2013 (Continued)
Outcomes “Data on quality of life, asthma control and patient confidence will be collected from both arms at baseline
and 3 and 6 months post-intervention. Data on health services resource use will be collected from all patient
records 6 months pre- and post-intervention. Semi-structured interviews will be carried out with healthcare
staff and a purposive sample of patients to elicit their views and experiences of the trial. The outcomes of
interest in this feasibility trial are the ability to recruit patients and healthcare staff, the optimal method
of delivering the intervention within routine clinical practice, and acceptability and perceived utility of the
intervention among patients and staff.”
Starting date Overall trial start date: 01/09/2012
Overall trial end date: 30/11/2013
Contact information Dr Gaylor Hoskins - Nursing Midwifery and Allied Health Professions (NMAHP) Research Unit, Iris Mur-
doch Building, University of Stirling
Notes
NCT02516449
Trial name or title Assessment of shared decision-making aids in asthma
Methods Randomised, parallel, double-blind study (investigators and outcome assessors blinded)
Participants Planned enrolment: 51
Men or women, aged 18 to 65 years, with current diagnosis of mild to severe asthma (details of asthma
eligibility given on clinicaltrials.gov)
People with COPD or recent asthma education (last 6 months) excluded
Interventions Patient decision aid that participants read and fill before being provided education on asthma. The decision
aid is a 12-page A3 booklet entitled “Should I take asthma inhaled controller medication to optimize asthma
control?”
Control group received no intervention.
Outcomes Primary outcomes: asthma knowledge measured by QCALF score and decisional conflict measured by DCS
score (both as change from baseline to 2 months)
Secondary outcomes: adherence to treatment, measured by questionnaire, and asthma control, measured by
ACSS score (both as change from baseline to 2 months)
Starting date March 2013 - Study authors confirmed that study was undergoing amendments at the time of writing of this
review
Contact information Louis-Philippe Boulet, MD, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie
de Quebec
Notes
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Tapp 2011
Trial name or title Comparative effectiveness of asthma interventions within a practice-based research network
Methods Unclear if randomised. A centralised database will be created with the goal of facilitating comparative effec-
tiveness research on asthma outcomes specifically for this study. Patient and community level analysis will
include results from patient surveys, focus groups, and asthma patient density mapping. Community variables
such as income and housing density will be mapped for comparison
Participants This study will include 95 practices, 171 schools, and more than 30,000 asthmatic patients
Interventions • Group A is the usual care control group without electronic medical record (EMR).
• Group B includes a second control group that has an EMR with decision support, asthma action plans,
and population reports at baseline. A time delay design during year 1 converts practices in Group B to
Group C after integrated approach to care intervention.
• Four practices within Group C will receive the shared decision-making intervention (and will become
Group D).
• Group E will receive a school-based care intervention through case management within the schools.
Outcomes Hospitalisations and emergency department visits; improved adherence to medication; improved quality of
life; reduced school absenteeism; improved self-efficacy;
improved school performance
Starting date Unclear
Contact information Lisa.Hebert@carolinashealthcare.org - Carolinas Physicians Network, Carolinas HealthCare System, Char-
lotte, NC
Notes
ACSS: Asthma Control Scoring System; COPD: chronic obstructive pulmonary disease; DCS: Decisional Conflict Scale; EMR:
electronic medical record; QCALF: self-administered French scale assessing four domains of asthma knowledge.
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D A T A A N D A N A L Y S E S
Comparison 1. Shared decision-making versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life improvement
(AQLQ responders)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2 Quality of life scores (ITG-ASF) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 ITG-ASF night-time
symptom scale
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 ITG-ASF daytime
symptom scale
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 ITG-ASF functional
limitation scale
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Quality of life scores
(mini-AQLQ)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Medication adherence 1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 All medications 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 ICS only 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Exacerbations of asthma 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Requiring hospital
admission
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Requiring ED visit 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Requiring specialist visit 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.4 Requiring GP visit 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Asthma well controlled 2 Odds Ratio (Fixed, 95% CI) Totals not selected
6.1 ACQ < 1 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 ACT > 22 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 ATAQ = 0 1 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Shared decision-making versus usual care, Outcome 1 Quality of life
improvement (AQLQ responders).
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 1 Quality of life improvement (AQLQ responders)
Study or subgroup SDM Usual care Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wilson 2010 (1) 128/182 105/189 1.90 [ 1.24, 2.91 ]
0.05 0.2 1 5 20
Favours usual care Favours SDM
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(1) SDM vs usual care. Unlcear if adjusted for clustering
Analysis 1.2. Comparison 1 Shared decision-making versus usual care, Outcome 2 Quality of life scores
(ITG-ASF).
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 2 Quality of life scores (ITG-ASF)
Study or subgroup SDM Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ITG-ASF night-time symptom scale
Fiks 2015 (1) 26 15.7 (17) 27 16.3 (17) -0.60 [ -9.76, 8.56 ]
2 ITG-ASF daytime symptom scale
Fiks 2015 (2) 26 12 (14) 27 8 (14) 4.00 [ -3.54, 11.54 ]
3 ITG-ASF functional limitation scale
Fiks 2015 (3) 26 9.3 (18.5) 27 5 (18.5) 4.30 [ -5.66, 14.26 ]
-50 -25 0 25 50
Favours usual care Favours SDM
(1) SDs estimated from p-value for difference between groups
(2) SDs estimated from p-value for difference between groups
(3) SDs estimated from p-value for difference between groups
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Analysis 1.3. Comparison 1 Shared decision-making versus usual care, Outcome 3 Quality of life scores
(mini-AQLQ).
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 3 Quality of life scores (mini-AQLQ)
Study or subgroup SDM Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wilson 2010 (1) 182 5.5 (1.06) 189 5.1 (1.06) 0.40 [ 0.18, 0.62 ]
-1 -0.5 0 0.5 1
Favours control Favours SDM
(1) mini-AQLQ symptom scale.
Analysis 1.4. Comparison 1 Shared decision-making versus usual care, Outcome 4 Medication adherence.
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 4 Medication adherence
Study or subgroup SDM Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All medications
Wilson 2010 (1) 182 0.67 (0.5) 189 0.46 (0.5) 0.21 [ 0.11, 0.31 ]
2 ICS only
Wilson 2010 (2) 182 0.59 (0.55) 189 0.37 (0.55) 0.22 [ 0.11, 0.33 ]
-0.5 -0.25 0 0.25 0.5
Favours usual care Favours SDM
(1) SDs estimated from p-value for the difference
(2) SDs estimated from p-value for the difference
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Analysis 1.5. Comparison 1 Shared decision-making versus usual care, Outcome 5 Exacerbations of asthma.
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 5 Exacerbations of asthma
Study or subgroup SDM Usual care Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Requiring hospital admission
Fiks 2015 0/26 1/27 0.33 [ 0.01, 8.56 ]
2 Requiring ED visit
Fiks 2015 2/26 6/27 0.29 [ 0.05, 1.60 ]
3 Requiring specialist visit
Fiks 2015 8/26 12/27 0.56 [ 0.18, 1.71 ]
4 Requiring GP visit
Fiks 2015 16/26 18/27 0.80 [ 0.26, 2.46 ]
0.005 0.1 1 10 200
Favours SDM Favours usual care
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Analysis 1.6. Comparison 1 Shared decision-making versus usual care, Outcome 6 Asthma well controlled.
Review: Shared decision-making for people with asthma
Comparison: 1 Shared decision-making versus usual care
Outcome: 6 Asthma well controlled
Study or subgroup log [Odds Ratio] Odds Ratio Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 ACQ < 1
van Bragt 2015 1.0986 (0.9789) 3.00 [ 0.44, 20.43 ]
2 ACT > 22
van Bragt 2015 0.2007 (1.0964) 1.22 [ 0.14, 10.48 ]
3 ATAQ = 0
Wilson 2010 0.6419 (0.2096) 1.90 [ 1.26, 2.87 ]
0.01 0.1 1 10 100
Favours usual care Favours SDM
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study ID Country Population Age (years) Design Intervention Aimed at Control
Clark 1998 USA 74 physicians;
637 children
1 to 12 Cluster RCT SDM seminars HCPs Usual care
Fiks 2015 USA 60 families 6 to 12 Individual RCT SDM portal HCPs and pa-
tients/parents
Usual care + de-
cision support
van Bragt
2015
Holland 33 children 6 to 12 Cluster RCT SDM online
tool
HCPs and pa-
tients/parents
Enhanced usual
care
Wilson 2010 USA 612 adults 18 to 65 Individual RCT SDM struc-
tured sessions
HCPs 1. Guideline-
led decision-
making
2. Usual care
HCP: healthcare provider; RCT: randomised controlled trial; SDM: shared decision-making.
45Shared decision-making for people with asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. “Parents’ Views of Pediatricians’ Performance”; adapted from Clark 1998
Was/did the clinician: SDM Control P value
(GEEa )
Reassuring and encouragingb 4.63 4.42 0.006
Look into how family managed
day to dayb
3.98 3.69 0.02
Describe how child should be
fully
activec
71.% 59% 0.007
Describe at least 1 of 3 goals:
child should sleep through the
night; have no symptoms when
active; be fully activec
75% 64% 0.07
Give information to relieve spe-
cific
worriesb
4.1 3.9 0.007
Enable family to know how to
make
asthmamanagement decisionsb
4.3 4.2 0.07
aGEE method to assess “Time2” (follow-up) scores with baseline scores and group assignment as covariates in regression models.
bA Likert-type response scale was used, where 1 = strongly disagree and 6 = strongly agree.
cQuestion asked at “Time2” (follow-up) only.
NB: A total of 472 parents were followed up; numbers in each group are not given.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
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Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
CENTRAL (the Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Condition search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
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6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
17. exp Aspergillosis, Allergic Bronchopulmonary/
18. lung diseases, fungal/
19. aspergillosis/
20. 18 and 19
21. (bronchopulmonar$ adj3 aspergillosis).mp.
22. 17 or 20 or 21
23. 16 or 22
24. Lung Diseases, Obstructive/
25. exp Pulmonary Disease, Chronic Obstructive/
26. emphysema$.mp.
27. (chronic$ adj3 bronchiti$).mp.
28. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
29. COPD.mp.
30. COAD.mp.
31. COBD.mp.
32. AECB.mp.
33. or/24-32
34. exp Bronchiectasis/
35. bronchiect$.mp.
36. bronchoect$.mp.
37. kartagener$.mp.
38. (ciliary adj3 dyskinesia).mp.
39. (bronchial$ adj3 dilat$).mp.
40. or/34-39
41. exp Sleep Apnea Syndromes/
42. (sleep$ adj3 (apnea$ or apnoea$)).mp.
43. (hypopnoea$ or hypopnoea$).mp.
44. OSA.mp.
45. SHS.mp.
46. OSAHS.mp.
47. or/41-46
48. Lung Diseases, Interstitial/
49. Pulmonary Fibrosis/
50. Sarcoidosis, Pulmonary/
51. (interstitial$ adj3 (lung$ or disease$ or pneumon$)).mp.
52. ((pulmonary$ or lung$ or alveoli$) adj3 (fibros$ or fibrot$)).mp.
53. ((pulmonary$ or lung$) adj3 (sarcoid$ or granulom$)).mp.
54. or/48-53
55. 23 or 33 or 40 or 47 or 54
Filter to identify randomised controlled trials (RCTs)
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1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 shared* NEAR decision*:ti,ab
#6 sharing* NEAR decision*:ti,ab
#7 informed* NEAR decision*:ti,ab
#8 informed* NEAR choice*:ti,ab
#9 decision* NEAR aid*:ti,ab
#10 ((share* or sharing* or informed*) AND (decision* or deciding* or choice*)):ti
#11 MeSH DESCRIPTOR Decision Making
#12 MeSH DESCRIPTOR Decision Support Techniques
#13 MeSH DESCRIPTOR Decision Support Systems, Clinical
#14 MeSH DESCRIPTOR Choice Behavior
#15 decision* NEAR making*:ti,ab
#16 decision* NEAR support*:ti,ab
#17 choice* NEAR behavio?r*:ti,ab
#18 ((decision* or choice*) AND (making* or support* or behavior* or behaviour*)):ti
#19 MeSH DESCRIPTOR Patient Participation
#20 patient* NEAR participation*:ti,ab
#21 consumer* NEAR participation*:ti,ab
#22 patient* NEAR involvement*:ti,ab
#23 consumer* NEAR involvement*:ti,ab
#24 ((patient* or consumer*) AND (involvement* or involving* or participation* or participating*)):ti
#25 MeSH DESCRIPTOR Professional-Patient Relations
#26 MeSH DESCRIPTOR Physician-Patient Relations
#27 MeSH DESCRIPTOR Patient-Centered Care
#28 ((patient* or person* or client* or consumer*) NEAR (centred or centered or focused or oriented)):ti,ab
#29 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
or #24 or #25 or #26 or #27 or #28
#30 #4 AND #29
(Note: In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, asthma.)
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C O N T R I B U T I O N S O F A U T H O R S
KK wrote the Background and Methods sections of this review with support from PM.
For the full review, KK, PM, and RN screened search results and selected studies for inclusion. KK and RN finalised the included
studies, extracted data, and assessed risk of bias in the included studies. KK conducted the analyses and wrote up the results, with input
from RN. RN and KK assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach. RN, PM, and KA wrote the Discussion section, with input from KK. All review authors contributed
to interpretation of findings and assisted in preparing the manuscript for submission.
D E C L A R A T I O N S O F I N T E R E S T
KK is funded to prepare Cochrane reviews by a Programme Grant awarded by the NIHR to the Cochrane Airways Group.
PM has reported no conflicts.
KA is a consultant respiratory paediatrician with respiratory interest in the NHS. He has no alternative sources of funding.
RN is a qualified general practitioner and the deputy Co-ordinating Editor of Cochrane Airways. She is funded by an NIHR grant to
Cochrane Airways.
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Internal sources
• Kayleigh M Kew, UK.
Supported by St George’s, University of London
External sources
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Evidence to guide care in adults and children with asthma, 13/89/14
This project was supported by the NIHR, via Cochrane Infrastructure, Cochrane Programme Grant, or Cochrane Incentive funding
to the Cochrane Airways Group. The views and opinions expressed therein are those of the review authors and do not necessarily
reflect those of the Systematic Reviews Programme, the NIHR, the NHS, or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the Dealing with missing data section, we changed the wording after “Where this was not possible, and we considered that the
missing data may introduce serious bias” from “we explored the impact of including such studies in the overall assessment of results
by a sensitivity analysis” to “we explored the impact in the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) rating for that outcome.”
Rebecca Normansell joined the review author team at the review stage. She extracted data and assessed studies for risk of bias, instead
of PM, as had been planned. This was a more practical approach, as KK and RN are based in the same office.
We had planned to exclude cross-over trials owing to the likelihood of carry-over of effects, but for future updates, we will include the
first phase of a cross-over trial. We did not identify any relevant cross-over trials during our searches.
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